OverviewSuggest Edit

OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics. Its leading compound is an immuno-oncology therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The product pipeline includes both active (vaccine) and passive (monoclonal antibody and antibody drug conjugate) therapeutics.
TypePublic
Founded2002
HQTW
Websiteobipharma.com

Latest Updates

Employees (est.) (Dec 2018)124
Share Price (Jul 2021)NT$109(-1%)
Cybersecurity ratingBMore

Key People/Management at OBI Pharma

Michael Chang

Michael Chang

Chief Executive Officer, Chairman
Tamon Tseng

Tamon Tseng

Director
Frank Chen

Frank Chen

Chief Financial Officer, Director
Yun Yen

Yun Yen

Director
Jerry G. Fong

Jerry G. Fong

Independent Director
Taychang Wang

Taychang Wang

Independent Director
Show more

OBI Pharma Office Locations

OBI Pharma has an office in San Diego
San Diego, CA, US
5959 Cornerstone Ct W Suite 200
Show all (3)

OBI Pharma Financials and Metrics

OBI Pharma Revenue

Market capitalization (21-Jul-2021)

21.5b

Closing stock price (21-Jul-2021)

109.0
OBI Pharma's current market capitalization is NT$21.5 b.
Show all financial metrics

OBI Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

OBI Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

OBI Pharma Online and Social Media Presence

Embed Graph

OBI Pharma News and Updates

OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network's OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

TAIPEI, Taiwan, April 26, 2021 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S.-based SWOG Cancer Research Network has started patient enrollment for a Phase I/II study of OBI-3424, a first-in-class (small-molecule prodrug) DNA...

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

TAIPEI, Taiwan, April 6, 2021 /PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174) today announced the data highlighting the characteristics and antitumor efficacy of OBI-3424 and animal studies of OBI-998, as well as the T-cell inhibitory roles of Globo-H and SSEA-4 in the tumor...

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

TAIPEI, Taiwan, Jan. 6, 2021 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development overview at the 39th Annual J.P. Morgan Digital Healthcare Conference on...

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

TAIPEI, Taiwan, Nov. 19, 2020 /PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4), today announced that data from the OBI-833 Phase 1 clinical study targeting the Globo H antigen...

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

TAIPEI, Taiwan, Sept. 14, 2020 /PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held...

OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II

TAIPEI, Taiwan, June 16, 2020 /PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4), today announced that data highlighting the role of Globo H antigen in cancer survival and its...
Show more

OBI Pharma Frequently Asked Questions

  • When was OBI Pharma founded?

    OBI Pharma was founded in 2002.

  • Who are OBI Pharma key executives?

    OBI Pharma's key executives are Michael Chang, Tamon Tseng and Frank Chen.

  • How many employees does OBI Pharma have?

    OBI Pharma has 124 employees.

  • Who are OBI Pharma competitors?

    Competitors of OBI Pharma include Tanvex Biopharma, Jiangsu Hansoh Pharmaceutical Group and 3sbio.

  • Where are OBI Pharma offices?

    OBI Pharma has an office in San Diego.

  • How many offices does OBI Pharma have?

    OBI Pharma has 3 offices.